Market Indices
Sector Heatmap
AXSM — Axsome Therapeutics, Inc
NasdaqAxsome Therapeutics, Inc
- O
- 182.55
- H
- 182.55
- L
- 175.46
- V
- 981.12K
AXSM — Latest News & Headlines
17 StoriesAxsome Therapeutics, Inc. (AXSM) Stock Price, News, Quote & History - Yahoo Finance
Axsome Therapeutics, Inc. (AXSM) Stock Price, News, Quote & History Yahoo Finance
Axsome Therapeutics (NasdaqGM:AXSM) Stock Forecast & Analyst Predictions - Simply Wall Street
Axsome Therapeutics (NasdaqGM:AXSM) Stock Forecast & Analyst Predictions Simply Wall Street
Axsome Therapeutics, Inc. (AXSM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Axsome Therapeutics, Inc. (AXSM) Stock Price, News, Quote & History Yahoo! Finance Canada
Axsome Therapeutics slides as investors weigh launch execution and policy risks - Quiver Quantitative
Axsome Therapeutics slides as investors weigh launch execution and policy risks Quiver Quantitative
Three in four caregivers wish they had recognized Alzheimer’s agitation sooner - Stock Titan
Three in four caregivers wish they had recognized Alzheimer’s agitation sooner Stock Titan
Axsome Therapeutics (NASDAQ:AXSM) Shares Down 5.4% on Analyst Downgrade - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Shares Down 5.4% on Analyst Downgrade MarketBeat
Responsive Playbooks and the AXSM Inflection - Stock Traders Daily
Responsive Playbooks and the AXSM Inflection Stock Traders Daily
AXSM Maintains Rating by Morgan Stanley -- Price Target Lowered to $247 - gurufocus.com
AXSM Maintains Rating by Morgan Stanley -- Price Target Lowered to $247 gurufocus.com
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), ClearPoint Neuro (CLPT) and Axsome Therapeutics (AXSM) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), ClearPoint Neuro (CLPT) and Axsome Therapeutics (AXSM) The Globe and Mail
Can Axsome Therapeutics (AXSM) Keep Justifying Its Price On Sales? - Simply Wall Street
Can Axsome Therapeutics (AXSM) Keep Justifying Its Price On Sales? Simply Wall Street
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Rating of "Moderate Buy" from Brokerages MarketBeat
H.C. Wainwright reiterates Axsome stock Buy rating at $290 target By Investing.com - in.investing.com
H.C. Wainwright reiterates Axsome stock Buy rating at $290 target By Investing.com in.investing.com
AXSM Q2 2026 Earnings: Wider-Than-Expected Loss per Share Meets a Modestly Positive Stock Reaction - Management Guidance Update - dars.gov.et
AXSM Q2 2026 Earnings: Wider-Than-Expected Loss per Share Meets a Modestly Positive Stock Reaction - Management Guidance Update dars.gov.et
Truist Raises Price Target on Axsome Therapeutics to $285 From $200, Keeps Buy Rating - Yahoo Finance
Truist Raises Price Target on Axsome Therapeutics to $285 From $200, Keeps Buy Rating Yahoo Finance
Axsome Therapeutics (NASDAQ:AXSM) Price Target Cut to $267.00 by Analysts at Deutsche Bank Aktiengesellschaft - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Price Target Cut to $267.00 by Analysts at Deutsche Bank Aktiengesellschaft MarketBeat
Is Axsome Therapeutics (AXSM) Undervalued As Caregiver Survey Data Tests Its CNS Growth Story? - Simply Wall Street
Is Axsome Therapeutics (AXSM) Undervalued As Caregiver Survey Data Tests Its CNS Growth Story? Simply Wall Street
AXSM270521P00110000 interactive stock chart | AXSM May 2027 110.000 put stock - uk.finance.yahoo.com
AXSM270521P00110000 interactive stock chart | AXSM May 2027 110.000 put stock uk.finance.yahoo.com